2023 World Conference on Lung Cancer (Posters)-EP13.07. RYZ101 (Ac-225 DOTATATE) Opportunity Beyond GEP-NETs: Preclinical Efficacy in Small Cell Lung Cancer

EP13.07. RYZ101 (Ac-225 DOTATATE) Opportunity Beyond GEP-NETs: Preclinical Efficacy in Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A study presented at a conference explored the potential of RYZ101 as a treatment for small-cell lung cancer (SCLC). RYZ101 is a radiopharmaceutical that targets somatostatin receptor 2 (SSTR2), which is overexpressed in SCLC. The study aimed to provide preclinical evidence for the use of RYZ101 in SCLC, either alone or in combination with standard chemotherapy.<br /><br />The study involved various experiments to assess the binding and internalization of RYZ101, its biodistribution and radiation dosage, as well as its anti-tumor activity. Results showed that RYZ101 had a high binding affinity to SSTR2 and demonstrated effective internalization in SSTR2 cells. In animal models, RYZ101 showed anti-tumor activity and inhibited tumor growth compared to control groups.<br /><br />These findings support the potential of RYZ101 as a treatment for SCLC and suggest that it may be more effective than standard chemotherapy. RYZ101's ability to selectively target cancer cells and its α-particle emitting properties make it a promising therapy for this aggressive form of lung cancer. The study also highlighted the ongoing Phase 1b trial of RYZ101 in combination with standard chemotherapy for patients with extensive-stage SSTR2 SCLC.<br /><br />Overall, the study provides evidence for the characterization and potential efficacy of RYZ101 as a treatment option for SSTR2-positive SCLC patients. The results warrant further investigation in clinical trials to determine the safety and effectiveness of RYZ101 in treating SCLC.

Asset Subtitle

Ye Yuan

Meta Tag

Speaker Ye Yuan

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

RYZ101

treatment

small-cell lung cancer

SCLC

radiopharmaceutical

somatostatin receptor 2

SSTR2

preclinical evidence

standard chemotherapy

binding affinity